[go: up one dir, main page]

TR200002790T2 - 5-(4-(2-(N-metil-N-2-piridil) amino)etoksi) benzil)tiazolidin-2,4-dion içeren terkip - Google Patents

5-(4-(2-(N-metil-N-2-piridil) amino)etoksi) benzil)tiazolidin-2,4-dion içeren terkip

Info

Publication number
TR200002790T2
TR200002790T2 TR2000/02790T TR200002790T TR200002790T2 TR 200002790 T2 TR200002790 T2 TR 200002790T2 TR 2000/02790 T TR2000/02790 T TR 2000/02790T TR 200002790 T TR200002790 T TR 200002790T TR 200002790 T2 TR200002790 T2 TR 200002790T2
Authority
TR
Turkey
Prior art keywords
thiazolidin
dione
pyridyl
ethoxy
benzyl
Prior art date
Application number
TR2000/02790T
Other languages
English (en)
Inventor
Patel Jai
Ross Hamish
Price Robin
Roger Granett Jeffrey
Nigel Wray Paul
Original Assignee
Smithkline Beecham P.L.C.
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham P.L.C., Smithkline Beecham Corporation filed Critical Smithkline Beecham P.L.C.
Publication of TR200002790T2 publication Critical patent/TR200002790T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Terkibin farmasötik olarak kabul edilebilir formda ve farmasötik olarak kabul edilebilir bir tasiyici içinde 2 ila12 mg Bilesik (I) içermesi ile karakterize edilen bir terkip;böyle bir terkibin ilaç yapiminda kullanilmasi;böyle bir terkibin ve böyle bir proseste faydali bir ara terkibin hazirlanmasi için prosesler.
TR2000/02790T 1997-06-05 1998-06-02 5-(4-(2-(N-metil-N-2-piridil) amino)etoksi) benzil)tiazolidin-2,4-dion içeren terkip TR200002790T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
TR200002790T2 true TR200002790T2 (tr) 2001-11-21

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2000/02790T TR200002790T2 (tr) 1997-06-05 1998-06-02 5-(4-(2-(N-metil-N-2-piridil) amino)etoksi) benzil)tiazolidin-2,4-dion içeren terkip
TR1999/02963T TR199902963T2 (tr) 1997-06-05 1998-06-02 5-[4-[2-(N-Metil-N-2-Piridil)Amino) Etoksi]Benzil]Tiazolidin-2,4-Dion içeren terkip

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR1999/02963T TR199902963T2 (tr) 1997-06-05 1998-06-02 5-[4-[2-(N-Metil-N-2-Piridil)Amino) Etoksi]Benzil]Tiazolidin-2,4-Dion içeren terkip

Country Status (29)

Country Link
EP (1) EP0998284A1 (tr)
JP (1) JP2001521553A (tr)
KR (1) KR20010013410A (tr)
CN (3) CN1112926C (tr)
AP (1) AP1214A (tr)
AR (2) AR008198A1 (tr)
AU (1) AU8215098A (tr)
BG (1) BG104048A (tr)
BR (1) BR9810405A (tr)
CA (2) CA2292629C (tr)
CO (1) CO4940400A1 (tr)
DZ (1) DZ2510A1 (tr)
EA (1) EA002384B1 (tr)
GB (1) GB9711683D0 (tr)
HU (1) HUP0004070A3 (tr)
ID (1) ID24264A (tr)
IL (1) IL133074A0 (tr)
MX (1) MXPA99011322A (tr)
NO (2) NO995938L (tr)
NZ (2) NZ523725A (tr)
OA (1) OA11306A (tr)
PE (1) PE78899A1 (tr)
PL (1) PL337201A1 (tr)
SK (1) SK164899A3 (tr)
TR (2) TR200002790T2 (tr)
TW (1) TW570797B (tr)
UY (1) UY25032A1 (tr)
WO (1) WO1998055122A1 (tr)
ZA (2) ZA9811572B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE60037602T2 (de) 1999-04-23 2009-01-08 Smithkline Beecham P.L.C., Brentford Herstellung einer polymorphen Form eines Thiazolidindionderivates
AR023561A1 (es) * 1999-04-23 2002-09-04 Smithkline Beecham Corp Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP1854794A1 (en) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
EP0777469A1 (en) * 1994-02-10 1997-06-11 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
EP0851757A2 (en) * 1995-08-10 1998-07-08 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
JP2000514807A (ja) * 1996-07-12 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー レプチン耐性の新規な治療

Also Published As

Publication number Publication date
EA002384B1 (ru) 2002-04-25
NZ513922A (en) 2001-09-28
HUP0004070A3 (en) 2002-03-28
NZ523725A (en) 2004-09-24
TR199902963T2 (tr) 2000-02-21
BG104048A (bg) 2000-07-31
CA2333352A1 (en) 1998-12-10
AR008198A1 (es) 1999-12-29
EP0998284A1 (en) 2000-05-10
CA2292629C (en) 2004-01-06
PE78899A1 (es) 1999-10-22
CN1112926C (zh) 2003-07-02
NO995938D0 (no) 1999-12-03
JP2001521553A (ja) 2001-11-06
PL337201A1 (en) 2000-08-14
IL133074A0 (en) 2001-03-19
DZ2510A1 (fr) 2003-01-25
SK164899A3 (en) 2000-11-07
AU8215098A (en) 1998-12-21
OA11306A (en) 2003-10-22
CN1259050A (zh) 2000-07-05
CA2292629A1 (en) 1998-12-10
AR015120A1 (es) 2001-04-18
GB9711683D0 (en) 1997-08-06
EA199901116A1 (ru) 2000-06-26
ZA9811572B (en) 1999-07-22
MXPA99011322A (es) 2004-12-02
TW570797B (en) 2004-01-11
AP9901696A0 (en) 1999-12-31
CO4940400A1 (es) 2000-07-24
NO995938L (no) 2000-02-02
WO1998055122A1 (en) 1998-12-10
CN1526391A (zh) 2004-09-08
UY25032A1 (es) 1998-11-26
ZA984826B (en) 1999-08-03
CN1430959A (zh) 2003-07-23
AP1214A (en) 2003-10-08
BR9810405A (pt) 2000-08-29
KR20010013410A (ko) 2001-02-26
HUP0004070A2 (hu) 2002-02-28
ID24264A (id) 2000-07-13
NO20040738L (no) 2000-02-02

Similar Documents

Publication Publication Date Title
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
TR200002790T2 (tr) 5-(4-(2-(N-metil-N-2-piridil) amino)etoksi) benzil)tiazolidin-2,4-dion içeren terkip
HRP20020416B1 (hr) Novi pripravak i upotreba
TR200103353T2 (tr) Bir füzyonlu heterosiklik bileşimin hidroklorid tuzu.
TR200001793T2 (tr) Yapısında değişiklik yapılmış tiyazolidinediyon türevi, bunun hazırlanması için işlem ve eczacılık alanında kullanımı
IL151917A0 (en) Inhibitors of dipeptidyl peptidase iv
DE59702414D1 (de) Dipeptidische benzamidine als kininogenasen-inhibitoren
JO2239B1 (en) Method for preparing benzothophen derivatives
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
HUT71351A (en) N-substituted 3-azabicyclo[3.2.0]heptane derivatives useful as neuroleptic agents
NZ504704A (en) Hydrate of 5-[4-[2- (N-methyl-N- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione maleic acid salt
AR015894A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos
HRP20000263B1 (en) Process for the preparation of thiazolidinedione derivatives
TR200103040T2 (tr) Yeni farmasötik maddeler
TR200103041T2 (tr) Yeni farmas”tik maddeler.
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
CZ20011832A3 (cs) Nový farmaceutický přípravek a způsob jeho přípravy
DE60122580D1 (de) 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidin-2,4-dion mesylatsalz
GB0021784D0 (en) Novel pharmaceutical
HRP20010344B1 (en) Novel method of treatment
AP1738A (en) Sodium salts of 5-[4-[2-(N-Methyl -N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
AP2002002684A0 (en) 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical
ECSP003434A (es) Nuevos compuestos